Immunotherapy Drugs Market

About the Report

About the Report

Global Immunotherapy Drugs Market-Drivers, Restraints, Opportunities, Trends, and Forecast up to 2025
[104 pages report] This market research report includes a detailed segmentation of the global immunotherapy drugs market by drug type (monoclonal antibodies, vaccine, non-specific immunotherapies, adaptive cell therapy, and others), by treatment area (cancer, inflammatory and autoimmune disease, infectious disease, and others), by regions (North America, Europe, Asia Pacific, and Rest of the World).
Overview of the Global Immunotherapy Drugs Market
Infoholic's market research report predicts that the Global Immunotherapy Drugs Market will grow at a CAGR of 12.5% during the forecast period. The market has witnessed steady growth in the past few years, and the introduction of novel products has increased the acceptance of immunotherapy drugs in the market. The market is fueled by an upsurge in the incidence of lifestyle and chronic disease globally, reduction in disease recurrence, increasing product approval, and high preference for immunotherapy over traditional chemotherapy.
 
 
The growing market trend continues and is becoming one of the increasingly accepted treatments across many countries worldwide. The manufacturers are focusing on new approvals, collaboration, and development of new products due to the increase in demand for immunotherapy drugs for the treatment of cancer and other diseases. Most of the revenue is generated from the leading players in the market with dominant sales such as AbbVie, Inc., Amgen, Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb, Johnson and Johnson, and Merck & Co., Inc.
According to Infoholic Research analysis, North America accounted for the largest share of the global immunotherapy drugs market in 2018. The US dominates the market owing to the presence of most of the immunotherapy drugs manufacturers in the region. Asia Pacific is expected to grow at the fastest rate during the forecast period, owing to factors such as growing incidence of lifestyle diseases, increasing adoption of novel treatment, and low manufacturing cost.
By Drug Type:
Monoclonal Antibodies (mAbs)
Vaccines
Non-specific Immunotherapies
Adaptive Cell Therapy
Others
The monoclonal antibodies segment occupied the largest share in 2018 and is expected to grow at low-double-digit CAGR during the forecast period. The adaptive cell therapy segment is expected to grow at a high CAGR during the forecast period 2019-2025.
By Treatment Area:
Cancer
Inflammation and Autoimmune Disease
Infectious Disease
Others
In 2018, the cancer segment occupied the largest share and is expected to grow at a high CAGR during the forecast period due to the rising incidence of cancer globally and increasing preference for immunotherapy as a first line of treatment.
By Regions:
North America
Europe
APAC
RoW
North America is dominant in the global immunotherapy drugs market, followed by Europe and Asia Pacific. The significant share of the North America market comes from the US due to the availability of favorable reimbursement policies.
Immunotherapy Drugs Market Research Competitive Analysis-The global immunotherapy drugs market has massive growth opportunities in both developed and developing regions. The introduction of a novel product with affordable drug cost is expected to increase the competition among the market players.
Many companies are currently focused on approvals, collaboration, and development of new products related to immunotherapy drugs due to increased demand for this therapy to treat various disease types.
For instance, in January 2019, BioNTech AG inked a deal with MAB Discovery GmbH to acquire MAB's operational antibody generation unit. The acquisition helps to expand BioNTech, which is a top privately-held developer of RNA-based therapeutics, further into monoclonal antibody (mAb) development to develop new treatments that combine technologies of both the companies. In June 2018, Novartis received European approval for Aimovig, for the prevention of migraine in adults, and it works by blocking the activity of calcitonin gene-related peptide (CGRP) that is involved in migraine attacks. It is the only treatment specifically designed for migraine prevention to be approved in the European Union. In addition, other leading vendors are focusing on hugely investing in R&D activities to develop new products to obtain a high share in the market.
Key Vendors:
AbbVie, Inc.
Amgen, Inc.
F. Hoffmann-La Roche Ltd.
Bristol-Myers Squibb
Johnson and Johnson
Merck & Co., Inc.
Key Competitive Facts
Increasing disease incidence, aging population, promising repayment or reimbursement plans in few nations, and enormous R&D activities for the immunotherapy drug development are the major factors driving the market growth.
With more than 8,000 ongoing trials for cancer immunotherapy, a huge amount of study concentrated on checkpoint inhibitors (CPi) and combinations with chemotherapies, targeted therapies, and other immune-oncology (IO) agents.
Benefits-The report provides complete details about the related sub-segments of the immunotherapy drugs market. Through this report, the key stakeholders can know about the major trends, drivers, investments, vertical player's initiatives, and government initiatives toward the disease management in the upcoming years along with details of the existing pure-play companies and new players entering the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders in order to expand their business and capture the revenue in specific verticals, and to analyze before investing or expanding the business in this market.
Key Takeaways:
Understanding the potential market opportunity with precise market size and forecast data.
A detailed market analysis focusing on the growth of the immunotherapy drugs industry.
Factors influencing the growth of the immunotherapy drugs market.
In-depth competitive analysis of dominant and pure-play vendors.
Prediction analysis of the immunotherapy drugs market in both developed and developing regions.
Key insights related to major segments of the immunotherapy drugs market.
Latest market trend analysis impacting the buying behavior of the consumers.
Key Stakeholders
 

Products


Companies

AbbVie, Inc., Amgen, Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb, Johnson and Johnson, and Merck & Co., Inc.

Table of Contents

Table of Contents

Table of Contents

1 Industry Outlook 9

1.1 Industry Overview 9

1.1.1 Global Driver for Pharmaceutical Demand 12

1.1.2 R&D Pipeline in Pharmaceutical Industry 12

1.1.3 Top Pharma Drugs by Sales (In USD Million) 13

1.2 Industry Trends 14

2 Report Outline 16

2.1 Report Scope 16

2.2 Report Summary 16

2.3 Research Methodology 17

2.4 Report Assumptions 18

3 Market Snapshot 19

3.1 Market Definition-Infoholic Research 19

3.2 Benefits of Immunotherapy 19

3.3 Segmented Addressable Market (SAM) 19

3.4 Trends of the Immunotherapy Drugs Market 20

3.5 Related Markets 21

3.5.1 Human Insulin 21

3.5.2 Oncology Drugs 22

4 Market Outlook 24

4.1 List of Cancer Immunotherapy Drugs Approved (2016- April 2019) 24

4.2 Market segmentation 26

4.3 PEST Analysis 27

4.4 Porter 5 (Five) Forces 28

5 Market Characteristics 29

5.1 DRO-Global Immunotherapy Drugs Market Dynamics 29

5.1.1 Drivers 29

5.1.1.1 High preference of immunotherapy over traditional chemotherapy 29

5.1.1.2 Growing incidence of lifestyle and chronic diseases 30

5.1.2 Opportunities 31

5.1.2.1 Emergence of biosimilars 31

5.1.2.2 Increasing opportunities in the emerging market 31

5.1.3 Restraints 32

5.1.3.1 High immunotherapy treatment costs 32

5.1.3.2 Complex manufacturing process 32

5.2 DRO-Impact Analysis 32

5.3 Key Stakeholders 33

6 Drug Type: Market Size and Analysis 35

6.1 Overview 35

6.2 Monoclonal Antibodies (mAbs) 36

6.3 Vaccine 38

6.4 Non-specific Immunotherapy 39

6.5 Adaptive Cell Therapy 40

6.6 Others 41

7 Treatment Area: Market Size and Analysis 43

7.1 Overview 43

7.2 Cancer 45

7.3 Inflammatory and Autoimmune Diseases 46

7.4 Infectious Disease 47

7.5 Others 48

8 Regions: Market Size and Analysis 50

8.1 Overview 50

8.2 North America 51

8.3 Europe 53

8.4 Asia Pacific 55

8.5 Rest of the World 56

9 Competitive Landscape 58

9.1 Overview 58

10 Vendor Profiles 61

10.1 AbbVie, Inc. 61

10.1.1 Overview 61

10.1.2 Geographic Revenue 63

10.1.3 Business Focus 64

10.1.4 SWOT Analysis 65

10.1.5 Business Strategies 65

10.2 Amgen, Inc. 66

10.2.1 Overview 66

10.2.2 Geographic Revenue 68

10.2.3 Business Focus 69

10.2.4 SWOT Analysis 69

10.2.5 Business Strategies 70

10.3 F. Hoffmann-La Roche Ltd. 70

10.3.1 Overview 70

10.3.2 Business Units 72

10.3.3 Geographic Revenue 73

10.3.4 Business Focus 73

10.3.5 SWOT Analysis 74

10.3.6 Business Strategies 75

10.4 Bristol-Myers Squibb 75

10.4.1 Overview 75

10.4.2 Geographic Revenue 78

10.4.3 Business Focus 79

10.4.4 SWOT Analysis 79

10.4.5 Business Strategy 80

10.5 Johnson & Johnson 81

10.5.1 Overview 81

10.5.2 Business Units 84

10.5.3 Geographic Revenue 85

10.5.4 Business Focus 86

10.5.5 SWOT Analysis 87

10.5.6 Business Strategies 87

10.6 Merck & Co., Inc. 88

10.6.1 Overview 88

10.6.2 Business Units 91

10.6.3 Geographic Revenue 92

10.6.4 Business Focus 93

10.6.5 SWOT Analysis 94

10.6.6 Business Strategies 94

11 Companies to Watch For 95

11.1 Novartis AG 95

11.1.1 Overview 95

11.2 GlaxoSmithKline plc 98

11.2.1 Overview 98

11.3 AstraZeneca PLC 100

11.3.1 Overview 100

11.4 Eli Lilly and Company Ltd 101

11.4.1 Overview 101

12 Annexure 103

12.1 Abbreviations 103


List of Figure

Charts

 

CHART 1 GLOBAL PRESCRIPTION DRUG SALES, 2018-2025 (USD BILLION) 10

CHART 2 GLOBAL OVER-THE-COUNTER DRUG MARKET REVENUE, 2018-2025, USD BILLION 10

CHART 3 GLOBAL PHARMA SALES, BIOLOGICS V/S NON-BIOLOGICS (%) 11

CHART 4 GLOBAL PHARMACEUTICAL SALES BY REGION, 2018 12

CHART 5 GLOBAL PHARMACEUTICAL R&D SPENDING (2010-2017) 13

CHART 6 PHARMACEUTICAL DRUGS BY SALES, 2018 (USD BILLION) 14

CHART 7 RESEARCH METHODOLOGY OF GLOBAL IMMUNOTHERAPY DRUGS MARKET 17

CHART 8 GLOBAL IMMUNOTHERAPY DRUGS MARKET REVENUE, 2018-2025 (USD BILLION) 20

CHART 9 SEGMENTATION OF GLOBAL IMMUNOTHERAPY DRUGS MARKET 26

CHART 10 PEST ANALYSIS OF GLOBAL IMMUNOTHERAPY DRUGS MARKET 27

CHART 11 PORTER 5 FORCES ON GLOBAL IMMUNOTHERAPY DRUGS MARKET 28

CHART 12 MARKET DYNAMICS-DRO ANALYSIS 29

CHART 13 DRO-IMPACT ANALYSIS OF GLOBAL IMMUNOTHERAPY DRUGS MARKET 32

CHART 14 KEY STAKEHOLDERS 33

CHART 15 GLOBAL IMMUNOTHERAPY DRUGS MARKET BY DRUG TYPE SEGMENTATION, 2018 AND 2025 (USD BILLION) 35

CHART 16 GLOBAL MONOCLONAL ANTIBODY MARKET REVENUE, 2018-2025 (USD BILLION) 37

CHART 17 GLOBAL VACCINE MARKET REVENUE, 2018-2025 (USD BILLION) 38

CHART 18 GLOBAL NON-SPECIFIC IMMUNOTHERAPY MARKET REVENUE, 2018-2025 (USD BILLION) 39

CHART 19 GLOBAL ADAPTIVE CELL THERAPY MARKET REVENUE, 2018-2025 (USD BILLION) 41

CHART 20 GLOBAL OTHERS MARKET REVENUE, 2018-2025 (USD BILLION) 42

CHART 21 GLOBAL IMMUNOTHERAPY DRUGS MARKET BY TREATMENT AREA SEGMENTATION, 2018 (%) 43

CHART 22 GLOBAL IMMUNOTHERAPY DRUGS MARKET BY TREATMENT AREA SEGMENTATION, 2025 (%) 44

CHART 23 GLOBAL CANCER MARKET REVENUE, 2018-2025 (USD BILLION) 45

CHART 24 GLOBAL INFLAMMATORY AND AUTOIMMUNE DISEASE MARKET REVENUE, 2018-2025 (USD BILLION) 46

CHART 25 GLOBAL INFECTIOUS DISEASE MARKET REVENUE, 2018-2025 (USD BILLION) 48

CHART 26 GLOBAL OTHERS MARKET REVENUE, 2018-2025 (USD BILLION) 48

CHART 27 GLOBAL IMMUNOTHERAPY DRUGS MARKET BY GEOGRAPHICAL SEGMENTATION, 2018 (%) 50

CHART 28 GLOBAL IMMUNOTHERAPY DRUGS MARKET BY GEOGRAPHICAL SEGMENTATION, 2025 (%) 51

CHART 29 IMMUNOTHERAPY DRUGS MARKET REVENUE IN NORTH AMERICA, 2018-2025 (USD BILLION) 52

CHART 30 IMMUNOTHERAPY DRUGS MARKET REVENUE IN EUROPE, 2018-2025 (USD BILLION) 54

CHART 31 IMMUNOTHERAPY DRUGS MARKET REVENUE IN ASIA PACIFIC, 2018-2025 (USD BILLION) 55

CHART 32 IMMUNOTHERAPY DRUGS MARKET REVENUE IN REST OF THE WORLD, 2018-2025 (USD BILLION) 57

CHART 33 ABBVIE INC.: OVERVIEW SNAPSHOT 62

CHART 34 ABBVIE INC.: GEOGRAPHIC REVENUE 63

CHART 35 ABBVIE INC.: SWOT ANALYSIS 65

CHART 36 AMGEN INC.: OVERVIEW SNAPSHOT 67

CHART 37 AMGEN INC.: GEOGRAPHIC REVENUE 68

CHART 38 AMGEN INC.: SWOT ANALYSIS 69

CHART 39 F. HOFFMANN-LA ROCHE LTD.: OVERVIEW SNAPSHOT 72

CHART 40 F. HOFFMANN-LA ROCHE LTD.: BUSINESS UNITS 72

CHART 41 F. HOFFMANN-LA ROCHE LTD.: GEOGRAPHIC REVENUE 73

CHART 42 F. HOFFMANN-LA ROCHE LTD.: SWOT ANALYSIS 74

CHART 43 BRISTOL-MYERS SQUIBB: OVERVIEW SNAPSHOT 78

CHART 44 BRISTOL-MYERS SQUIBB: GEOGRAPHIC REVENUE 78

CHART 45 BRISTOL-MYERS SQUIBB: SWOT ANALYSIS 79

CHART 46 JOHNSON & JOHNSON: OVERVIEW SNAPSHOT 84

CHART 47 JOHNSON & JOHNSON: BUSINESS UNITS 84

CHART 48 JOHNSON & JOHNSON: GEOGRAPHICAL REVENUE 85

CHART 49 JOHNSON & JOHNSON: SWOT ANALYSIS 87

CHART 50 MERCK & CO., INC.: OVERVIEW SNAPSHOT 90

CHART 51 MERCK & CO., INC.: BUSINESS UNITS 91

CHART 52 MERCK & CO., INC.: GEOGRAPHICAL REVENUE 92

CHART 53 MERCK & CO., INC.: SWOT ANALYSIS 94

 

 


List of Table

Tables

 

TABLE 1 LIST OF CANCER IMMUNOTHERAPY DRUGS APPROVED (2016-APRIL 2019) 24

TABLE 2 GLOBAL IMMUNOTHERAPY DRUGS MARKET REVENUE BY DRUG TYPE, 2018-2025 (USD BILLION) 35

TABLE 3 GLOBAL IMMUNOTHERAPY DRUGS MARKET REVENUE BY TREATMENT AREA, 2018-2025 (USD BILLION) 44

TABLE 4 GLOBAL IMMUNOTHERAPY DRUGS MARKET REVENUE BY REGIONS, 2018-2025 (USD BILLION) 51

TABLE 5 GLOBAL IMMUNOTHERAPY DRUGS MARKET BY VENDOR RANKING, 2018 60

TABLE 6 OTHER PROMINENT VENDORS OF IMMUNOTHERAPY DRUGS MARKET 60

TABLE 7 ABBVIE INC.: OFFERINGS 61

TABLE 8 ABBVIE INC.: RECENT DEVELOPMENTS 61

TABLE 9 AMGEN INC.: OFFERINGS 66

TABLE 10 AMGEN INC.: RECENT DEVELOPMENTS 66

TABLE 11 F. HOFFMANN-LA ROCHE LTD.: PRODUCT OFFERINGS 71

TABLE 12 F. HOFFMANN-LA ROCHE LTD.: RECENT DEVELOPMENTS 71

TABLE 13 BRISTOL-MYERS SQUIBB: OFFERINGS 75

TABLE 14 BRISTOL-MYERS SQUIBB: RECENT DEVELOPMENT 75

TABLE 15 JOHNSON & JOHNSON: PRODUCT OFFERINGS 81

TABLE 16 JOHNSON & JOHNSON: RECENT DEVELOPMENTS 81

TABLE 17 MERCK & CO., INC.: PRODUCT OFFERINGS 88

TABLE 18 MERCK & CO., INC.: RECENT DEVELOPMENTS 89

TABLE 19 NOVARTIS AG: SNAPSHOT 95

TABLE 20 NOVARTIS AG: RECENT DEVELOPMENTS 95

TABLE 21 GLAXOSMITHKLINE PLC: SNAPSHOT 98

TABLE 22 GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS 98

TABLE 23 ASTRAZENECA PLC: SNAPSHOT 100

TABLE 24 ASTRAZENECA PLC: RECENT DEVELOPMENTS 100

TABLE 25 ELI LILLY AND COMPANY LTD: SNAPSHOT 101

TABLE 26 ELI LILLY AND COMPANY LTD: RECENT DEVELOPMENTS 101

 

You can also purchase parts of this report. Do you want to check out a section wise price list?

Why Buy From US?

RRR
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

reach
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Research
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

Insite
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository
150+ Consulting project a year
100+ Analysts
8000+ Client Queries in 2022

What Our Clients Say About Us

Want the same for your business? Talk To Our Expert